Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04526691 · ClinicalTrials.gov registry record · Phase 1
Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)
A Phase 1 study of Advanced or Metastatic NSCLC, sponsored by Daiichi Sankyo.
- Active
- Registry status
- Phase 1
- Development phase
- 145
- Enrollment target
- 20
- Study locations
NCT04526691 is a Phase 1 study of Advanced or Metastatic NSCLC that is active but no longer recruiting, run by Daiichi Sankyo. The registered enrollment target is 145 participants. The trial reports 20 study locations across 9 states.
The verdict
NCT04526691, a Phase 1 study of Advanced or Metastatic NSCLC, is active but no longer recruiting, sponsored by Daiichi Sankyo.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 145 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will assess safety and treatment activity of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab with or without platinum chemotherapy in participants with advanced or metastatic non-small cell lung cancer.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Cisplatin
- DRUG Datopotamab deruxtecan
- DRUG KEYTRUDA®
Study Locations (20)
Other
- Instituto Europeo Di Oncologica - Milan
- Azienda Ospedaliera San Gerardo - Monza
- Istituto Nazionale Tumori Fondazione G. Pascale di Napoli Struttura di Oncologia - Naples
- National Cancer Center Hospital East - Chiba
- National Cancer Center Hospital - Tokyo
- Showa Medical University Hospital - Tokyo
- H. Vall Hebrón (Vall Hebron Institut de Oncologia - VHIO) - Barcelona
- START Madrid - Hospital Universitario Fundacion Jimenez Diaz - Madrid
- Hospital Universitario 12 de Octubre - Madrid
- (CIOCC-START) Hospital Universitario HM Sanchinarro - Madrid
- Hospital Puerta de Hierro - Majadahonda
Maryland
- Johns Hopkins Kimmel Cancer Center at Bayview - Baltimore
- The Skip Viragh Outpatient Cancer Building - Baltimore
Arizona
- Mayo Clinic - Scottsdale
California
- City of Hope - Duarte
District of Columbia
- Johns Hopkins Kimmel Cancer Center - Washington D.C.
Florida
- Mayo Clinic - Jacksonville
Minnesota
- Mayo Clinic - Rochester
New Mexico
- Quantum Santa Fe - Santa Fe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2020-09-15 |
| Est. Completion | 2026-04-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04526691
The ClinicalTrials.gov registry entry for NCT04526691 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 145 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced or Metastatic NSCLC appearing as the primary indexed condition, and to 4 interventions - of which Carboplatin is the first listed.
NCT04526691 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, Maryland, Arizona.
Frequently Asked Questions
What is clinical trial NCT04526691 about?
NCT04526691 is a clinical study titled "Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)". This study will assess safety and treatment activity of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab with or without platinum chemotherapy in participants with advanced or metastatic non-small cell lung cancer.
What is the current status of trial NCT04526691?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 145 participants. The study started on 2020-09-15. Estimated completion is 2026-04-15.
What conditions does trial NCT04526691 study?
This clinical trial studies the following conditions: Advanced or Metastatic NSCLC.
What interventions are being tested in trial NCT04526691?
The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Datopotamab deruxtecan (DRUG), KEYTRUDA® (DRUG).
Who is sponsoring clinical trial NCT04526691?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04526691 being conducted?
This trial has 20 study locations across Arizona, California, District of Columbia, Florida, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced or Metastatic NSCLC
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.